Erteberel is under clinical development by Eli Lilly and Co and currently in Phase II for Post Menopausal Mood Disorder. According to GlobalData, Phase II drugs for Post Menopausal Mood Disorder does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Erteberel LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Erteberel overview
Erteberel (LY500307) is under development for the treatment of estradiol-withdrawal-induced mood symptoms in women with past perimenopausal depression. The drug candidate is administered orally in the form of capsule. It is a benzopyran derivative that selectively targets estrogen receptor (ER) beta. It was also under development for the treatment of benign prostatic hyperplasia (BPH). It was under development for the treatment of negative symptoms, cognitive impairment associated with schizophrenia (CIAS).
See Also:
Eli Lilly and Co overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa, and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
For a complete picture of Erteberel’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
